APP and Alzheimer disease: In conclusion, our study demonstrate that BS-I can reduce the Aβ level in the brains of AD mice, protect neurons from injury, improve the activity of anti-oxidative enzymes and ameliorate cognitive impairment in the APP/PS1 mouse model.